{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polycythaemia-erythrocytosis/background-information/complications-prognosis/","result":{"pageContext":{"chapter":{"id":"69cfa130-4762-5abc-9ddf-36ad93773d75","slug":"complications-prognosis","fullItemName":"Complications and prognosis","depth":2,"htmlHeader":"<!-- begin field e3166668-58c5-4996-bc37-19fb43a2ec19 --><h2>What are the complications and prognosis?</h2><!-- end field e3166668-58c5-4996-bc37-19fb43a2ec19 -->","summary":"","htmlStringContent":"<!-- begin item 84568e3e-0edc-4be8-b723-c07a99713b93 --><!-- begin field 4759ee1f-9cae-4bb3-9b96-46670c9b74ce --><ul><li><strong>Erythrocytosis leads to increased blood viscosity, and elevated risk of thrombosis.</strong> A 34 year follow-up study of 5,209 men and women found that those with haematocrit values in the highest quintile had a statistically significant, approximately 2.7-fold increased risk of mortality due to cardiovascular disease compared to those with lower values. </li><li><strong>For people with polycythaemia vera:</strong><ul><li>Overall, the risk of thrombosis is 1.6-fold higher than in the background population. Cardiovascular risk and mortality rate are increased accordingly.<ul><li>People below the age of 60 years, with no history of thrombosis, and without other risk factors for cardiac disease such as hypertension, diabetes, hyperlipidaemia, or smoking, are considered to be at low thrombotic risk.</li><li>People below the age of 60 years, with no history of thrombosis, but who have traditional cardiac risk factors such as hypertension, diabetes, hyperlipidaemia, or smoking, are considered to be at intermediate risk.</li><li>People over the age of 60 years, or those with any history of thrombosis are considered to be at high risk of thrombosis. </li><li>Treatment with aspirin, venesection, and cytoreductive therapies significantly reduce these risks.</li></ul></li><li>The risk of haemorrhage may also be increased, particularly in people with severe thrombocytosis.</li><li>Within 15 years of diagnosis, in 6% to 15% of people the disease will progress to the myelofibrotic stage, where the bone marrow is replaced by dense fibrous bands of reticulin and cytopenias are common.</li><li>Rarely, progression to acute myeloid leukaemia occurs.</li></ul></li><li><strong>For people with secondary erythrocytosis:</strong><ul><li>The prognosis is largely determined by the nature of any underlying condition.</li></ul></li><li><strong>For people with apparent erythrocytosis:</strong><ul><li>Evidence from small non-randomised studies indicates increased morbidity and mortality. However, it is unclear whether this is directly due to increased haematocrit values, or related to other factors.</li><li>There is no robust evidence that reducing the haematocrit reduces morbidity or mortality.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">Gagnon et al, 1994</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">Keohane et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">BMJ Best pracrice, 2016</a>] </p><!-- end field 4759ee1f-9cae-4bb3-9b96-46670c9b74ce --><!-- end item 84568e3e-0edc-4be8-b723-c07a99713b93 -->","topic":{"id":"fa6be70e-4297-5c9a-b3cd-9583f15e3111","topicId":"fd54e0c5-4fe5-450d-9784-91b5e47c8754","topicName":"Polycythaemia/erythrocytosis","slug":"polycythaemia-erythrocytosis","lastRevised":"Last revised in September 2020","chapters":[{"id":"695f9a30-5f1b-5c8c-b771-0c9194a05dbe","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7dd62db3-3d83-5397-87de-2926d3fd4a22","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fe394ca3-8f2b-5b5b-97cf-db1e470cb964","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"63325ec1-5a65-517d-b0aa-d0e73bebbfca","slug":"changes","fullItemName":"Changes"},{"id":"d7d77004-b1a3-5b51-b127-56e529c85135","slug":"update","fullItemName":"Update"}]},{"id":"43b989c9-04a9-5339-b325-9131b5be941b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd6ff7fe-7c84-572b-8476-d38ff3f127b6","slug":"goals","fullItemName":"Goals"},{"id":"b5793099-ce5d-5936-b15e-74b920fb9648","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ff345f15-3d9a-5bde-8daf-a7935cbaf03a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f3fd1887-7475-5781-8fbf-fe5899828386","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e0f239a5-035b-518f-b47b-e9c2ba32eac2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37e2c554-6ed2-5a18-aaeb-04351cd1273a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d7d4ea60-5030-5464-990d-fa4317fe399e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8bd9e0dc-e10a-53f3-8c7b-9385de985b19","slug":"definition","fullItemName":"Definition"},{"id":"82d6faa0-d4d9-5b16-8749-a562fb4b9c4a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"492c4d23-53a9-5d43-ac41-bbf40de526d8","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"69cfa130-4762-5abc-9ddf-36ad93773d75","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"5c705230-ec55-58d0-83c7-3782f3fff5c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"09648da8-6172-59c1-aba9-f14b74a1e6a9","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"089b1374-e8b4-5137-a954-4b1f90ee4a45","fullItemName":"Management","slug":"management","subChapters":[{"id":"46e0c8f9-21ea-5ab6-a9ed-601bfd74f61c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7cc68f5a-878e-564c-97aa-93d8d958e493","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"155ff0de-0d61-5d85-8d21-e9e9cee45889","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8c94b288-e2c4-56e8-8f74-a64ecc4a7198","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2439e91-a3f2-5e18-a9d5-5e82382bce20","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"98ba96ac-671e-5fdc-bf1e-b66cf9498201","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"da8ecf5e-0c5a-5650-b332-70e4aba2d39b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b7583d4-db4f-5b06-a69f-04a4f75b8cbb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c2217823-75aa-544d-ab7d-25d4d3f09c5c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d7d4ea60-5030-5464-990d-fa4317fe399e","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}